Increased expression of the B-cell-regulatory molecule CD72 in primary Sjögren's syndrome

Tissue Antigens

Volumn 63, Issue 3, 2004, Pages 255-259

  Smith, A J F ^a,b   Gordon, T P ^a   Macardle, P J ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

BAFF; CD72; Primary Sj gren's syndrome

Indexed keywords

B LYMPHOCYTE ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD22 ANTIGEN; CD72 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; MONOCLONAL ANTIBODY; POKEWEED MITOGEN; PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGED; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AUTOANTIBODIES; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CELL ADHESION MOLECULES; FEMALE; HUMANS; LECTINS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, COMPLEMENT 3D; SJOGREN'S SYNDROME; UP-REGULATION;

PHYTOLACCACEAE;

EID: 1542359013     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2004.00187.x     Document Type: Article

References (21)

1. Talal N. What is Sjögren's syndrome and why is it important? J Rheumatol Suppl 2000: 61: 1-3.
2. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis 1994: 53: 637-47.
3. Jonsson R, Haga H-G, Gordon T. Sjögren's syndrome. In: Koopman WJ, ed. Arthritis and Allied Conditions - A Textbook of Rheumatology, 14th edn. Philadelphia: LippincottWilliams and Wilkins, 2001: 1736-59.
4. Ravetch JV, Lanier L. Immune inhibitory receptors. Science 2000: 290: 84-9.
5. Holland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999: 72: 149-77.
6. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000: 165: 6635-43.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988: 31: 315-24.
8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982: 25: 1271-7.
9. Zola H. Detection of cytokine receptors at the cell surface by flow cytometry. In: Robinson JP, Darzynkiewicz Z, Dean NO et al., eds. Current Protocols in Cytometry. New York: Wiley Press, 1995.
10. Jamin C, Lamour A, Pennec YL, Hirn M, LeGoff P, Youinou P. Expression of CD5 and CD72 on T and B cell subsets in rheumatoid arthritis and Sjögren's syndrome. Clin Exp Immunol 1993: 92: 245-50.
11. Van de Velde H, Hoegen I, Luo W, Parnes J, Thielemans K. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991: 351: 662-5.
12. Kumanogoh A, Kikutani H. The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol 2001: 22: 670-6.
13. Wu H-J, Bondada S. Positive and negative roles of CD72 in B cell function. Immunol Res 2002: 25: 155-66.
14. Wu H-J, Venkataraman C, Estus S, Dong C, Davis RJ, Flavell RA et al. Positive signaling through CD72 induces mitogen-activated protein kinase activation and synergizes with B cell receptor signals to induce X-linked immunodeficiency B cell proliferation. J Immunol 2001: 167: 1263-73.
15. Venkataraman C, Lu P-J, Buhl A, Chen C-S, Cambier J, Bondada S. CD72-mediated B cell activation involves recruitment of CD19 and activation of phosphatidylinositol 3-kinase. Eur J Immunol 1998: 28: 3003-16.
16. Wu Y, Nadler MJ, Brennan LA, Gish GD, Timms JF, Fusaki N et al. The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol 1998: 8: 1009-17.
17. Watanabe C, Kumanogoh A, Shi W, Suzuki K, Yamada S, Okabe M et al. Enhanced immune responses in transgenic mice expressing a truncated form of the lymphocyte semaphorin CD100. J Immunol 2001: 167: 4321-8.
18. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002: 2: 465-75.
19. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002: 109: 59-68.
20. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999: 190: 1697-710.
21. Ying H, Healy JI, Goodnow CC, Parnes JR. Regulation of mouse CD72 gene expression during B lymphocyte development. J Immunol 1998: 161: 4760-7.